2023-08-11 16:18:32 ET
- Jasper Therapeutics press release ( NASDAQ: JSPR ): Q2 GAAP EPS of -$0.15 in-line.
- Cash and cash equivalents as of June 30, 2023, were $115.8 million, compared to $38.3 million as of December 31, 2022. The increase in cash and cash equivalents was due to net proceeds from the Company’s public offering in January 2023 and sales through its at-the-market facility in January 2023.
- Cash and cash equivalents are expected to be sufficient to fund the Company’s planned operating and capital expenditures through 2024.
- Shares +1.4% .
For further details see:
Jasper Therapeutics GAAP EPS of -$0.15 in-line